Filip Knop, MD

Filip Knop, MD
 

Diabetes Research Division
Department of Internal Medicine
Gentofte University Hospital
Copenhagen, Denmark


What are the physiologic properties of incretin system-targeting agents?

What are the physiologic properties of incretin system-targeting agents?

What are the PK/PD properties for GLP-1 RAs and how do these differences affect their clinical roles? And specifically, how do long- vs. short-acting GLP-1 RAs affect PPG vs FPG?

What are the PK/PD properties for GLP-1 RAs and how do these differences affect their clinical roles? And specifically, how do long- vs. short-acting GLP-1 RAs affect PPG vs FPG?

Based on physiologic properties, which patients are eligible for short- vs long-acting GLP-1 RAs? And why is the combination of basal insulin and GLP-1 RA a reasonable strategy?

Based on physiologic properties, which patients are eligible for short- vs long-acting GLP-1 RAs? And why is the combination of basal insulin and GLP-1 RA a reasonable strategy?